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Abstract:
Background: Prescribed Minimum Benefit Chronic Disease List (PMB CDL) conditions are a regulated list of  conditions most 
common to South Africa.
Objectives: To investigate the prevalence and association between PMB CDL conditions and age and gender among  patients 
with concomitant hypertension, diabetes and dyslipidaemia.
Methods: The study population consisted of  patients (n = 17 866) with a prescription containing at least one co-prescribed 
antilipemics, antihypertensive and antidiabetic (identified using the MIMS Desk Reference). ICD-10 codes on claims for PMB 
CDL conditions were counted.
Results: 39.5% of  patients had a PMB CDL condition.  Women had higher odds for hypothyroidism (OR 6.30, 95% CI; 5.52, 
7.19, p < 0.001) and lower odds for coronary artery disease (CAD) (OR 0.63, 95% CI; 0.55, 0.72, p < 0.001) than men. In com-
bination with hypothyroidism the odds for CAD were reversed and strongly increased; 3.54 (95% CI; 2.38, 5.25, p < 0.001). 
The odds for females having cardiac failure (CF) was insignificant and low (OR 0.87, 95% CI; 0.75, 1.01, p = 0.063); however 
combined with hypothyroidism, the odds increased to 5.35 (95% CI; 3.52, 8.13, p < 0.001).
Conclusion: Hypothyroidism was an important discriminating factor for co-morbidity in women with concomitant hyperten-
sion, diabetes and dyslipidaemia, in particular with cardiovascular disease.
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Introduction
In a commentary published in The Lancet, Salisbury1 de-
scribed the existence of  multi-morbidity (defined as “sev-
eral chronic disorders in one individual”) as the “norm 
rather than the exception”, citing the management of  
these patients as the “most important task facing health 
services in developed countries.” Salisbury described 
several reasons for the importance of  multi-morbidity, 
including an ageing population with a large number of  
chronic illnesses, greater longevity, and a subsequent rap-
idly growing need for health care services associated with 
an increasing financial burden.
Developing countries such as South Africa are not ex-
empt from the effects of  an aging population as shown 
by the United Nations population statistics.2 Compared 
to the 5% for the African continent en bloc, the percent-
age of  South Africans over the age of  60 years in 2012 
was noticeably higher at 9%, displaying similar levels of  
aging as nations in Central America, Micronesia, Polyne-
sia and South-Eastern Asia.2 Based on statistics from the 
World Health Organization, the burden from chronic dis-
ease (mainly cardiovascular diseases, cancers, chronic re-
spiratory diseases and diabetes) in South Africa are two to 
three times higher than that in developed countries.3 The 
first South African National Health and Nutrition Ex-
amination Survey (SANHANES-1)4 conducted in 2012, 
showed that elderly South Africans (65 years and older) 
in general had the highest self-reported rates for chron-
ic conditions. At the national level, 16.5% of  all respon-
dents indicated that they had high blood pressure, fol-
lowed by diabetes (5.0%), high blood cholesterol (4.2%), 
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heart disease (2.2%) and stroke (1.8%). Females had sig-
nificantly higher self-reported rates than males; howev-
er, the rates of  all chronic conditions tended to increase 
with age among both sexes.4 Similar to several developed 
countries,5-9 approximately half  of  elderly patients in the 
private health sector of  South Africa suffer from more 
than one chronic disease, with some being diagnosed for 
up to eleven conditions.10
The South African private health sector is administered 
largely by health insurance schemes (provided by medical 
schemes, i.e. medical insurance packages made up from 
of  a group of  participating members). This sector serves 
less than 20% of  the population’s needs, yet consumes 
more than 50% (maybe as high as 80%) of  the total 
health care expenditure in South Africa or approximate-
ly seven times more per capita than the public sector.11 
Beneficiaries 65 years old or older represent 6.5% of  this 
population.12 Already in 2009, the burden of  chronic dis-
eases in South Africa was noted to be on the rise resulting 
in a higher demand for chronic care.13 To curb the ex-
penditure on health care in the private sector the South 
African Government enacted a range of  regulations, in-
ter alia the application of  a Prescribed Minimum Benefit 
Chronic Disease List (or PMB CDL).  By definition, the 
PMB CDL, as a feature of  the Medical Schemes Act, 131 
of  1998, is a regulated compilation of  25 conditions re-
quiring treatment for over 12 months that are most com-
mon to the country, are considered to be life-threatening, 
and conditions where cost-effective treatment will sus-
tain and improve the quality of  the member’s life. Medical 
schemes are obliged to cover the costs related to the diag-
nosis, treatment and ongoing care of  these conditions, to 
the extent that this is provided for by way of  a therapeutic 
algorithm for the specified condition.14-15 
Chronic conditions often cluster in the elderly,16 because 
of  common pathways.17 The metabolic syndrome is typi-
cally characterized by the variable clustering of  metabolic 
abnormalities or risk factors that increases a person’s risk 
for atherosclerotic cardiovascular disease.18 According to 
the American Heart Association/National Heart, Lung 
and Blood Institute (AHA/NHLBI)19, the presence of  
any three of  five traits can constitute a diagnosis, from: 
(1) elevated waist circumference (≥102 cm in men and 
≥88cm in women); (2) elevated triglycerides of  ≥1.7 
mmol/L (or on drug treatment for elevated triglycerides); 
(3) reduced HDL cholesterol <1.03 mmol/L in men and 
<1.3 mmol/L in women (or on drug treatment for re-
duced HDL cholesterol); (4) elevated blood pressure 
measured as systolic blood pressure ≥130 mmHg or dia-
stolic blood pressure ≥85 mmHg (or on antihypertensive 
drug treatment in a patient with a history of  hyperten-
sion); and (5) elevated fasting glucose ≥5.6 mmol/L (or 
on drug treatment for elevated glucose).19 
The prevalence of  PMB CDL conditions in South African 
patients with metabolic syndrome-traits is not known.20-23 
The present study contributes to bridging the knowledge 
gap by aiming to investigate the prevalence of  PMB CDL 
conditions in South African private health care patients 
with metabolic syndrome-traits (i.e. concomitant hyper-
tension, diabetes and dyslipidaemia), and association 




Design, data source and study population
The flow diagram of  selection of  eligible patients for 
analysis is shown in Figure 1.  A cross-sectional analysis 
was conducted using a database obtained from a South 
African Pharmaceutical Benefit Management compa-
ny (PBM).  The database for the period 1 January to 31 
December 2008 contained pharmaceutical claims infor-
mation for a total of  974 497 patients (538 254 women; 
436 243 men), representing 12.4% of  the total medical 
scheme industry across South Africa during 2008.24  Us-
ing drug prescriptions as surrogates for disease state, we 
selected all patients that had a paid claim for a prescrip-
tion containing one or more co-prescribed antilipidemics, 
antihypertensives and antidiabetics. Antilipodemics, and 
antidiabetics were identified using the annual MIMS Desk 
Reference (MDR)25 for 2008.  These claimants, were re-
garded as patients with concomitant hypertension, diabe-
tes and dyslipidaemia (n = 17 866; male-to-female ratio 
1.17, mean age 63.7 (SD 11.98) years) (Figure 1). 
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We queried data fields for patient demographic infor-
mation (patients’ member number and dependent code, 
gender and date of  birth), and pertinent prescription in-
formation (such as drug trade name, date of  treatment 
and ICD-10 code per claim). The variables ‘date of  birth’ 
and ‘date of  treatment’ were used to calculate the age of  
patients on the day of  treatment.  ICD-10 codes specified 
for reimbursement purposes on paid prescription claims 
were used to identify PMB CDL conditions in the study 
population. Presence of  PMB CDL conditions were fur-
ther used to categorize metabolic syndrome patients with 
concomitant hypertension, diabetes and dyslipidaemia 
into groups, viz. those with PMB CDL conditions (one 
or multiple) and those without (Fig. 1). 
Identification of  PMB CDL conditions
PMB CDL conditions were identified based on presence 
of  the following ICD-10 codes on claims reimbursed 
from patients’ PMB benefits: Addison’s disease (ICD-
10 code E27.1), asthma (J45, J45.8), bronchiectasis (J47, 
Q33.4), cardiac failure (I50, I50.0, I50.1), cardiomyopathy 
(I42, I42.0, I25.5), chronic obstructive pulmonary dis-
ease (J43, J44), chronic renal disease (N03, N11, N18), 
coronary artery disease (I20, I20.0, I25), Crohn’s disease 
(K50, K50.8), diabetes insipidus (E23.2), dysrhythmias 
(I47, I47.2, I48), epilepsy (G40, G40.8), glaucoma (H40, 
Q15.0), hemophilia (D66, D67), hypothyroidism (E02, 
E03, E03.8), multiple sclerosis (G35), Parkinson’s disease 
(G20, G21), rheumatoid arthritis (M05, M06, M08.0), 
schizophrenia (F20), systemic lupus erythematosus (M32, 
L93, L93.2) and ulcerative colitis (K51, K51.9).14,15
Statistical analysis
Variables were characterized using 95% confidence inter-
vals and descriptive statistics such as proportions/ratios 
for categorical variables, and means and standard devia-
tions for continuous variables. An independent two-sam-
ple t-test (assuming unequal variances) was used to assess 
the statistical significance of  the age difference between 
men and women. Spearman's rank-order correlation test 
was performed to assess the relationship between the 
number of  PMB CDL conditions per patient and pa-
tients’ age.  Cross-tabulation with chi-squared statistics 
was used to assess the association between the number of  
PMB CDL conditions per patient and patients’ gender. 
 
We further performed logistic regression analysis to assess 
the association between the specific PMB CDL condition 
and patients’ gender, and calculated odds ratios (ORs) and 
associated 95% Wald confidence intervals (95% CI).  For 
the univariate model, the independent variable was gen-
der [(female (1), male (0)], with each PMB CDL condition 
as the dependent variable [with present (1), absent (0)]. 
Prevalence of  chronic disease,26–33 in general, increases 
with age.  For the adjusted model, we therefore included 
age as co-variate. Age-adjusted odds ratios, however, did 
not differ from the crude odds ratio by more than 10%.  
Because statistical significance tests yielded small p-values 
(indicating significance) in most tests, we focused our in-
terpretation on effect sizes which is independent of  units 
and sample size. Cohen's d-value was used to evaluate 
mean differences between groups (with  significance de-
Total number of beneficiaries on 
the database: January 1, 2008 –
December 31, 2008
(N = 974,497)
(436,243 male; 538,254 female)
All patients with concomitant 
hypertension, diabetes and 
dyslipidaemia
(N = 17,866)
(9,632 male; 8,234 female)
Patients with concomitant 
hypertension, diabetes and 
dyslipidaemia, with other PMB 
CDL conditions
(n = 7,050)
Patients with concomitant 
hypertension, diabetes and 
dyslipidaemia, without PMB 
CDL conditions
(n = 10,816)
Figure 1. The flow diagram of  selection of  eligible patients for analysis
Legend: PMB CDL conditions = Prescribed Minimum Benefit Chronic Disease List conditions. 
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fined as a level of  at least 0.8).  Spearman’s correlation co-
efficient was used for the strength of  association between 
ranked variables, and Cramér’s V statistics (defined as a 
level of  at least 0.5) was used for associations between 
categorical variables.  Odds ratios in contingency tables 
were interpreted using guidelines by Steyn34,where an OR 
>2 was interpreted as a moderate effect, and larger than 
3.64 as practically significant. Statistical analyses were per-
formed using SAS Software, version 9.3.35
 
Ethical considerations
The study was conducted with the approval of  the Re-
search Ethics Committee of  North-West University 
(Potchefstroom campus), and the board of  directors 
of  the PBM.  As per confidentiality agreement with the 
PBM supplying the data, all identifying information about 
beneficiaries, medical schemes, health plans, service pro-
viders and prescribers were encrypted or removed by the 
PBM before data was released for analysis.
 
Results
Table 1 shows the basic demographic characteristics 
of  the study population. A total of  7,050 patients with 
concomitant hypertension, diabetes and dyslipidaemia 
(39.5%) had one or more PMB CDL conditions during 
the study period.  Women (n = 3,791) of  this group of  
patients were on average significantly older than men (n 
= 3,259) at 67.58 ± 11.9 (95% CI, 67.2-68.0) and 66.74 
± 11.4 (95% CI, 66.3-67.1) years, respectively.  However, 
Cohen’s d-value showed no practical difference (d-value 
= 0.07).
Of  those with PMB CDL conditions, 5,061 (71.8%) had 
one condition, a further 1,626 (23.1%) had two condi-
tions, 302 (4.3%) had three conditions, 52 (0.7%) had 
four conditions and a further 9 patients had the maxi-
mum of  five PMB CDL conditions (average number of  
PMB CDL conditions per patient 1.34 ± 0.61, 95% CI; 
1.33, 1.36).  The most prevalent PMB CDL conditions 
overall were hypothyroidism, coronary artery disease and 
cardiac failure, experienced by 35.5%, 23.5%, and 22.6% 
of  patients from the study population with PMB CDL 
conditions (n = 7,050), respectively (Table 1).  The rela-
tionship between the number of  PMB CDL conditions 
per patient and patients’ age was significant, however, 
Spearman's rank-order correlation test showed that this 
association was weak (rs =0.205, p < 0.001).  Cross-tab-
ulation further showed that there was no association be-
tween the number of  PMB CDL conditions per patient 
and patients’ gender (p = 0.802, Cramér’s V = 0.01).  
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Tables 2 and 3 shows the univariate and age-adjusted 
odds ratios for the presence of  single and two co-pres-
ent PMB CDL conditions among females compared with 
males, respectively.  Women had higher odds of  having 
hypothyroidism than men (OR, 6.30, 95% CI; 5.52, 7.19, 
p < 0.001) (Table 2), which was deemed practically signif-
icant.  In addition, the presence of  hypothyroidism con-
ferred a significant effect on the odds of  women experi-
encing several of  the other PMB CDL conditions.  For 
instance, the higher odds of  women having rheumatoid 
arthritis (OR, 1.82, 95% CI; 1.01, 3.30, p = 0.047) (Table 
2) were strongly increased in co-presence of  hypothy-
roidism (OR, 4.69, 95% CI; 1.57, 14.02, p = 0.006), and 
practically significant.)  Furthermore, the odds of  wom-
en having prevalent asthma, epilepsy, and cardiomyopa-
thy that were near unity and not statistically significant 
as single PMB CDL conditions (Table 2), increased to be 
statistically and practically significant in combination with 
hypothyroidism (Table 3).  
Elderly females furthermore had a significant ‘advantage’ 
over men against having prevalent cardiovascular con-
ditions (ranging from 1.3 times lower odds for cardiac 
failure to 1.9 times lower odds for dysrhythmia than men 
in age-adjusted analysis) (Table 2).  This advantage per-
sisted, and increased strongly in the co-presence of  other 
cardiovascular PMB CDL conditions.  For instance, the 
age-adjusted odds of  having co-present cardiac failure 
and dysrhythmia, and co-present coronary artery disease 
and dysrhythmia were, respectively, 1.9 and 2.4 times low-
er in women than men from the study population (Table 
3).  
Table 1. Descriptive statistics 
 




Study population  
(N = 17,866) 
        
Total nr of patients, n (%) 8,234 (46.1) 9,632 (53.9)     
Age, mean ± SD [95% CI] 65.04 ± 12.3  
[64.8 65.3] 
62.60 ± 11.6  
[62.4 62.8] 
<0.001 0.19* 
Patients with PMB CDL conditions  
(n = 7 050) 
        
Total nr of patients, n (%) 3,791 (53.8) 3,259 (46.2)     
Age, mean ± SD [95% CI] 67.58 ± 11.9  
[67.2 68.0] 
66.74 ± 11.4  
[66.3 67.1] 
0.003 0.07* 
Average nr of PMB CDL per patient,  
mean ± SD [95% CI] 
1.34 ± 0.6  
[1.32 1.36] 





Prevalence of PMB CDL conditions  
overall 
        
Addison's disease, n (%) 4 (0.1) 6 (0.2) 0.529 0.010** 
Asthma, n (%) 522 (13.8) 491 (15.1) 0.122 0.018** 
Bronchiectasis, n (%) 0 1 (0.03) 0.462 0.013** 
Cardiac failure, n (%) 754 (19.9) 839 (25.7) <0.001 0.070** 
Cardiomyopathy, n (%) 248 (6.5) 369 (11.3) <0.001 0.084** 
Chronic obstructive pulmonary disease, n 
(%) 
60 (1.6) 125 (3.8) <0.001 0.070** 
Chronic renal disease, n (%) 15 (0.4) 14 (0.4) 0.825 0.003** 
Coronary artery disease, n (%) 665 (17.5) 990 (30.4) <0.001 0.151** 
Crohn’s disease, n (%) 5 (0.1) 3 (0.09) 0.733 0.006** 
Diabetes insipidus, n (%) 3 (0.08) 1 (0.03) 0.629 0.010** 
Dysrhythmias, n (%) 319 (8.4) 503 (15.4) <0.001 0.109** 
Epilepsy, n (%) 136 (3.6) 137 (4.2) 0.181 0.016** 
Glaucoma, n (%) 249 (9.2) 315 (9.7) <0.001 0.057** 
Haemophilia, n (%) 0 0     
Hypothyroidism, n (%) 1,996 (52.7) 509 (15.6) <0.001 0.386** 
Multiple sclerosis, n (%) 2 (0.05) 1 (0.03) 1.000 0.005** 
Parkinson’s disease, n (%) 54 (1.4) 65 (2.0) 0.064 0.022** 
Rheumatoid arthritis, n (%) 70 (1.9) 37 (1.1) 0.015 0.029** 
Schizophrenia, n (%) 12 (0.3) 11 (0.3) 0.878 0.002** 
Systemic lupus erythematosus, n (%) 5 (0.1) 1 (0.03) 0.227 0.017** 
Ulcerative colitis, n (%) 2 (0.05) 3 (0.09) 0.668 0.007** 
 
*Cohen’s d-value, **Cramer’s V. PMB CDL conditions = Prescribed Minimum Benefit Chronic Disease List conditions. Percentages for 
PMB CDL conditions were calculated using the total number of women (n = 3 791) and men (n = 3 259) in the data subset as 
denominator. 
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Table 2. Odds ratios with 95%Wald Confidence Intervals (95% CI) for single Prescribed Minimum 
Benefit Chronic Disease List (PMB CDL) conditions in patients with concomitant hypertension, diabetes 
and dyslipidaemia 
 
PMB CDL conditions n 
  
Model 1 
OR [95% Wald 
CI] 
p-value Model 2 





6.30 [5.52 7.19] <0.001 6.38 [5.58 7.28] <0.001 
Rheumatoid arthritis (28F, 18M) 1.82 [1.01 3.30] 0.047 1.84 [1.02 3.34] 0.044 
Asthma (252F, 264M) 1.12 [0.94 1.34] 0.204 1.14 [0.96 1.36] 0.134 
Parkinson's disease (26F, 31M) 0.98 [0.58 1.65] 0.943 0.80 [0.47 1.35] 0.398 
Epilepsy (68F, 84M) 0.95 [0.69 1.31] 0.737 0.98 [0.71 1.35] 0.891 
Cardiac failure (323F, 432M) 0.87 [0.75 1.01] 0.063 0.78 [0.68 0.91] 0.001 
Cardiomyopathy (109F, 152M) 0.84 [0.65 1.07] 0.159 0.80 [0.63 1.03] 0.087 
Schizophrenia (7F, 10M) 0.82 [0.31 2.15] 0.685 0.82 [0.31 2.16] 0.686 
Glaucoma (128F, 190M) 0.79 [0.63 0.98] 0.036 0.71 [0.56 0.89] 0.003 
Coronary artery disease (339F, 617M) 0.63 [0.55 0.72] <0.001 0.60 [0.52 0.69] <0.001 
Dysrhythmia (108F, 205M) 0.61 [0.48 0.77] <0.001 0.54 [0.42 0.68] <0.001 
Chronic obstructive pulmonary 
disorder 
(18F, 41M) 0.51 [0.29 0.89] 0.018 0.45 [0.26 0.79] 0.005 
Data are odds ratios (OR) (95% Wald confidence interval (CI)). Conditions with frequencies (n) < 5 were excluded from the analyses. For the 
univariate model, the dependent variable was gender [(female (1), male (0)], with the type of PMB CDL condition as the independent variable 
[with present (1), absent (0)]. 
M = Male; F = Female; Model 1 = Univariate (crude) model; Model 2 = Age adjusted model; OR = Odds ratio; aOR = Age adjusted odds 
ratio 
Table 3. Odds ratios with 95% Wald Confidence Intervals (95% CI) for two Prescribed Minimum Benefit 
Chronic Disease List (PMB CDL) conditions in patients with concomitant hypertension, diabetes and 
dyslipidaemia 
 
PMB CDL conditions n 
  
Model 1 
OR [95% Wald 
CI] 
p-value Model 2 
aOR [95% Wald 
CI] 
p-value 
Asthma / Hypothyroidism (103F, 22M) 5.53 [3.49 8.78] <0.001 5.46 [3.44 8.68] <0.001 
Epilepsy / Hypothyroidism (23F, 5M) 5.39 [2.05 14.19] 0.001 5.60 [2.12 14.77] 0.001 
Cardiac failure  
/ Hypothyroidism 
(122F, 27M) 5.35 [3.52 8.13] <0.001 4.65 [3.05 7.07] <0.001 
Glaucoma / Hypothyroidism (42F, 10M) 4.93 [2.47 9.84] <0.001 4.61 [2.30 9.21] <0.001 
Rheumatoid arthritis  
/ Hypothyroidism 
(16F, 4M) 4.69 [1.57 14.02] 0.006 4.71 [1.57 14.13] 0.006 
Cardiomyopathy  
/ Hypothyroidism 
(45F, 13M) 4.07 [2.19 7.54] <0.001 3.71 [2.00 6.91] <0.001 
Coronary artery disease  
/ Hypothyroidism 
(99F, 33M) 3.54 [2.38 5.25] <0.001 3.16 [2.12 4.70] <0.001 
Dysrhythmia / Hypothyroidism (85F, 58M) 1.74 [1.25 2.43] 0.001 1.44 [1.03 2.03] 0.033 
Asthma / Chronic obstructive 
pulmonary disease 
(10F, 11M) 1.06 [0.45 2.51] 0.888 0.98 [0.41 2.32] 0.957 
Coronary artery disease / 
Cardiac failure 
(68F, 84M) 0.95 [0.69 1.31] 0.737 0.77 [0.56 1.07] 0.118 
Asthma / Cardiac failure (29F, 38M) 0.89 [0.55 1.45] 0.645 0.82 [0.50 1.34] 0.429 
Asthma / Glaucoma (9F, 13M) 0.81 [0.35 1.90] 0.627 0.70 [0.30 1.66] 0.422 
Cardiac failure / Dysrhythmia (42F, 76M) 0.65 [0.44 0.94] 0.023 0.53 [0.36 0.78] 0.001 
Asthma / Dysrhythmia (9F, 17M) 0.62 [0.28 1.39] 0.245 0.54 [0.24 1.22] 0.137 
Coronary artery disease / 
Glaucoma 
(12F, 23M) 0.61 [0.30 1.23] 0.165 0.48 [0.24 0.96] 0.039 
Coronary artery disease / 
Asthma 
(13F, 27M) 0.56 [0.29 1.09] 0.089 0.53 [0.27 1.04] 0.063 
Cardiac failure / Glaucoma (10F, 22M) 0.53 [0.25 1.12] 0.097 0.41 [0.19 0.87] 0.020 
Asthma / Cardiomyopathy (14F, 31M) 0.53 [0.28 0.99] 0.047 0.49 [0.26 0.93] 0.030 
Coronary artery disease / 
Dysrhythmia 
(10F, 23M) 0.51 [0.24 1.07] 0.074 0.42 [0.20 0.89] 0.023 
Coronary artery disease / 
Cardiomyopathy 
(23F, 55M) 0.49 [0.30 0.79] 0.004 0.40 [0.24 0.65] <0.001 
Cardiomyopathy / Dysrhythmia (8F, 22M) 0.43 [0.19 0.96] 0.038 0.36 [0.16 0.81] 0.013 
Dysrhythmia / Glaucoma (4F, 12M) 0.39 [0.13 1.21] 0.103 0.30 [0.10 0.93] 0.037 
Cardiac failure / Chronic 
obstructive pulmonary disease 
(4F, 17M) 0.28 [0.09 0.82] 0.020 0.23 [0.08 0.69] 0.009 
  
Data are odds ratios (OR) (95% Wald confidence interval (CI)). Conditions with frequencies (n) < 5 were excluded from the analyses. For the 
univariate model, the dependent variable was gender [(female (1), male (0)], with the type of PMB CDL condition as the independent variable 
[with present (1), absent (0)]. 
M = Male; F = Female; Model 1 = Univariate (crude) model; Model 2 = Age adjusted model; OR = Odds ratio; aOR = Age adjusted odds 
ratio 
Table 3. Odds ratios with 95% Wald Confidence Intervals (95% CI) for two Prescribed Minimum Benefit 
Chronic Disease List (PMB CDL) conditions in patients with concomitant hypertension, diabetes and 
dyslipidaemia 
 
PMB CDL conditions n 
  
Model 1 
OR [95% Wald 
CI] 
p-value Model 2 
aOR [95% Wald 
CI] 
p-value 
Asthma / Hypothyroidism (103F, 
22M) 
5.53 [3.49 8.78] <0.001 5.46 [3.44 8.68] <0.001 
Epilepsy / Hypothyroidism (23F, 5M) 5.39 [2.05 14.19] 0.001 5.60 [2.12 14.77] 0.001 




5.35 [3.52 8.13] <0.001 4.65 [3.05 7.07] <0.001 
Glaucoma / Hypothyroidism (4 , 10M) 4.93 [2.47 9.84] <0.001 4.61 [2.30 9.21] <0.001 
Rheumatoid arthritis  
/ Hypothyroidism 
(16F, 4M) 4.69 [1.57 14.02] 0.006 4.71 [1.57 14.13] 0.006 
Cardiomyopathy  
 ypothyroidism 
(45F, 13M) 4.07 [2.19 7.54] <0.001 3.71 [2.00 6.91] <0.001 
oronary artery disease  
 ypothyroidism 
(99F, 33M) 3.54 [2.38 5.25] <0.001 3.16 [2. 2 4.70] <0.001 
Dysrhythmia / 
Hypothyroidis  
(85F, 58M) 1.74 [1.25 2.43] 0.001 1.44 [1.03 2.03] 0.033 
Asthma / Chronic 
obstructive pulmonary 
disease 
(10F, 11M) 1.06 [0.45 2.51] 0.888 0.98 [0.41 2.32] 0.957 
Coronary artery disease / 
Cardiac failure 
(68F, 84M) 0.95 [0.69 1.31] 0.737 0.77 [0.56 1.07] 0.118 
Asthma / Cardiac failure (29F, 38M) 0.89 [0.55 1.45] 0.645 0.82 [0.50 1.34] 0.429 
Asthma / Glaucoma (9F, 13M) 0.81 [0.35 1.90] 0.627 0.70 [0.30 1.66] 0.422 
Cardiac failure / 
Dysrhythmia
(42F, 76M) 0.65 [0.44 0.94] 0.023 0.53 [0.36 0.78] 0.001 
Asthma / Dysrhythmia (9F, 17M) 0.62 [0.28 1.39] 0.245 0.54 [0.24 1.22] 0.137 
Coronary artery disease / 
Glaucoma 
(12F, 23M) 0.61 [0.30 1.23] 0.165 0.48 [0.24 0.96] 0.039 
Coronary artery disease / 
Asthma 
(13F, 27M) 0.56 [0.29 1.09] 0.089 0.53 [0.27 1.04] 0.063 
Cardiac failure / Glaucoma (10F, 22M) 0.53 [0.25 1.12] 0.097 0.41 [0.19 0.87] 0.020 
Asthma / Cardiomyopathy (14F, 31M) 0.53 [0.28 0.99] 0.047 0.49 [0.26 0.93] 0.030 
Coronary artery disease / 
Dysrhythmia 
(10F, 23M) 0.51 [0.24 1.07] 0.074 0.42 [0.20 0.89] 0.023 
Coronary artery disease / 
a diomyopathy 
(23F, 55M) 0.49 [0.30 0.79] 0.004 0.40 [0.24 0.65] <0.001 
r iomyopathy / 
Dysrhythmia 
(8F, 22M) 0.43 [0.19 0.96] 0.038 0.36 [0.16 0.81] 0.013 
Dysrhythmia / Glaucoma (4F, 12M) 0.39 [0.13 1.21] 0.103 0.30 [0.10 0.93] 0.037 
Cardiac failure / Chronic 
obstructive pulmonary 
disease 
(4F, 17M) 0.28 [0.09 0.82] 0.020 0.23 [0.08 0.69] 0.009 
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In combination with coronary artery disease and dys-
rhythmia, respectively, the age-adjusted odds for cardio-
myopathy were 2.5–2.8 times lower for women than for 
men (Table 3).  It should be noted that this two-com-
bined cardiovascular PMB CDL conditions were present 
in only 416 of  the 17,866 patients from our study pop-
ulation (prevalence ratio (male:female) 1.7).  Moreover, 
co-present hypothyroidism not only reversed the appar-
ent ‘advantage’ afforded by being female against preva-
lent cardiovascular disease (e.g. cardiac failure, cardiomy-
opathy, coronary artery disease and dysrhythmia) (Table 
2), but increased the odds considerably (Table 3).  The 
odds for the co-presence of  hypothyroidism with cardiac 
failure (OR, 5.35, 95% CI; 3.52, 8.13, p < 0.001) and car-
diomyopathy (OR, 4.07, 95% CI; 2.19, 7.54, p < 0.001), 
respectively, were deemed practically significant.
Discussion
This large cross-sectional study of  medical claims data 
revealed that a nearly 40% of  patients with concomitant 
hypertension, diabetes and dyslipidaemia presented with 
several of  the other Prescribed Minimum Benefit Chron-
ic Disease List (PMB CDL) conditions. We further found 
that hypothyroidism was the single most prevalent PMB 
CDL condition encountered by about four times more in 
women than men.  These findings are in line with trends 
in international literature showing that hypothyroidism 
may be up to 10 times more frequent in women than 
men,36-39 especially among adults in middle age and in the 
elderly.39-40 The relatively high prevalence of  hypothyroid-
ism in elderly women from our study population further-
more accords with recent studies suggesting an associa-
tion between thyroid disease and the several of  the traits 
for the metabolic syndrome.41–46 This association in older 
adults may be ascribed to the pathophysiology of  thyroid 
hormone functions on lipid and glucose metabolism, and 
blood pressure. It has also been suggested that abnor-
malities in thyroid function may be secondary to weight 
excess.47-50 These functions are beyond the scope of  this 
manuscript. It is, however, conceivable that women from 
our study population showed a higher likeliness for hypo-
thyroidism compared with their male counterparts. Evi-
dence in support of  this includes the data from the 2012 
SANHANES-1 demonstrating that 64% of  women in 
contrast to 31% of  men older than 15 years in South Af-
rica are either overweight or obese.4 One in ten South Af-
rican males furthermore had a waist circumference equal 
to or larger than 102 cm, while more than half  of  females 
had a waist circumference equal to/or larger than 88 cm. 
In addition, the overall prevalence of  familial hypercho-
lesterolemia in South Africa was estimated as high as 1:7 
compared with 1:500 worldwide.51 Almost one out of  
four participants from the 2012 SANHANES-1 demon-
strated an abnormally high serum total-, and LDL-choles-
terol, and one out of  two had abnormally low HDL-cho-
lesterol. This prevalence of  abnormal serum total- and 
LDL-cholesterol was higher among females than males.4 
Females partaking in the SANHANES-1 furthermore 
had significantly higher self-reported high blood pressure 
and high blood sugar rates than males. Overall, one out 
five participants older than 45 years of  age had hyperten-
sion. Another one out of  five participants had impaired 
glucose homeostasis, whereas one out of  ten participants 
had diabetes. Both impaired glucose homeostasis and di-
abetes prevalence increased with age, reaching a peak in 
the groups aged 45–54 years and 55–64 years.4
Our results furthermore showed that being female ac-
corded a protective effect against prevalent cardiovascu-
lar conditions (cardiac failure, cardiomyopathy, coronary 
artery disease and dysrhythmias).  In combination with 
hypothyroidism, however, this advantage was reversed, 
and the odds strongly increased.  The metabolic syn-
drome represents a major risk factor for the development 
of  CVD.18,52-53 The magnitude of  this increased risk bur-
den varies according to which components of  the syn-
drome are present,53 as well as to the number of  compo-
nents present.54  The contribution of  several metabolic 
disorders to the metabolic syndrome is different in men 
and women.55,56 These gender differences may contribute 
towards gender differences in CVD.57–59 Hypothyroidism 
per se represents a risk factor for the development of  
cardiovascular disease.60–63 Because both metabolic syn-
drome and hypothyroidism are independent risk factors 
for cardiovascular disease, it is possible that patients suf-
fering from both these disease entities may have a com-
pounded risk. It is therefore possible that patients from 
our study population with at least three of  the metabolic 
syndrome traits (i.e. concomitant hypertension, diabetes 
and dyslipidaemia) with / and hypothyroidism showed 
a higher likeliness for cardiovascular disease.  It should 
be noted, however, that potential effect modification and 
confounding were outside the scope of  the current de-
scriptive analyses, and therefore not considered in this 
paper. 
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Strengths and limitations
The study population comprised of  patients from the 
South African private health sector, registered as benefi-
ciaries of  several medical schemes. This limits the external 
validity of  the study in that results cannot be generalised 
to the total South African population.  Furthermore, the 
presence of  confounding variables on the database, such 
as severity of  illness, smoking status, patients’ socio-eco-
nomic status, ethnicity, family history of  illness, and alco-
hol use, medical scheme the patient belonged to, and plan 
type/option was not recorded on research database  and 
hence, could not be controlled for.  The database, howev-
er, did contain pharmaceutical claims data for a total of  
974,497 patients at baseline, thereby increasing the power 
and accuracy for sub-group analyses.  Furthermore, there 
was no missing data fields in the data set.  Data quali-
ty was ascertained by several automated validation pro-
cesses that were applied in-house by the PBM, such as 
data integrity validation and eligibility services, utilization 
management services, clinical management services and 
pricing management along with real-time benefit man-
agement.
To increase the validity of  the diagnoses and to avoid 
counting transitory or accidental diagnoses, we counted 
only PMB CDL conditions if  they were coded in associa-
tion with claims paid from a patient’s PMB benefits.  The 
PMBs were developed to ensure that all medical scheme 
members have access to certain minimum health services, 
regardless of  the benefit option they have selected.14,15 
There is certainly always the probability that some pa-
tients’ data may not been have recorded on the claims da-
tabase for reimbursement because of  prescribers follow-
ing a different treatment regimen than that published in 
the algorithms, resulting in patients paying out-of-pocket 
for expenses for medication associated with the treatment 
of  the PMB CDLs. This may lead to under ascertainment 
in the prevalence of  PMB CDL conditions in these pa-
tients.  We, however, assumed that this would be only a 
small percentage of  patients because medical schemes are 
obliged to cover the costs related to the diagnosis, treat-
ment and on-going care of  the PMB CDL conditions, 
irrespective of  the patients’ medical plan or option.
Conclusion
The findings of  this large cross-sectional study revealed 
strong associations of  several of  the Prescribed Minimum 
Benefit Chronic Disease List conditions among patients 
with concomitant hypertension, diabetes and dyslipidae-
mia, indicating gender as determining factor for these 
types of  conditions. Concomitant hypertension, diabetes 
and dyslipidaemia indicating gender as determining factor 
for these types of  conditions.  This is, to our knowledge, 
the first time that these associations were assessed using 
claims data in South Africa.  We were furthermore able 
to support clinically derived knowledge by using medi-
cine claims data, with the recognition of  hypothyroidism 
as an important discriminating factor for co-morbidity 
in women with concomitant hypertension, diabetes and 
dyslipidaemia in particular with cardiovascular disease. 
Longitudinal research is clearly needed to reveal the time-
line for the development of  this condition and its causal 
inferences with the defining risk factors specific to the 
metabolic syndrome.  This will enable health care prac-
titioners to exercise pro-active care. By being pro-active 
in the management of  patients with multiple co-morbid-
ities, disease burden and potential health care costs can 
be limited. 
Control of  health care expenditure in the next decade 
will be one of  the major challenges facing the South Af-
rican economy with escalating costs identified as a key 
threat to future reforms in the South African health care 
industry.64,65 With the current lack of  electronically cap-
tured resource utilization data in the public sector, data 
collected from the private sector can be used to generate 
forecasts with well-characterized accuracies about the fu-
ture or diagnoses about states of  a patient that cannot be 
inspected directly.66,67  Considering that the PMB CDL in-
cludes chronic conditions for which medical schemes are 
compelled to provide benefits and full management pay-
ment with no co-payments,14,15 such data is fundamental 
to planning and decision-making in South African health 
departments, especially when planning the implementa-
tion of  a National Health Insurance System as is current-
ly mooted by government.
 
References
1. Salisbury C. Multimorbidity: redesigning health care for 
people who use it. Lancet 2012; 380(9836):7-9.  PubMed
2. United Nations. Department of  Economics and So-
cial Affairs. Population Division. World population 2012. 
[homepage on the internet] c2012 [cited 2014 July 4]. 
Available from www.unpopulation.org
3. World Health Organization. The Global Burden of  
Disease: 2004 Update. Geneva: WHO; 2008.
African Health Sciences Vol 17 Issue 1, March, 201795
4. Shisana O, Labadarios D, Rehle T, et al. South Afri-
can National Health and Nutrition Examination Sur-
vey (SANHANES-1): 2014 Edition. Cape Town: HSRC 
Press; 2014.
5. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, 
Guthrie B. Epidemiology of  multimorbidity and impli-
cations for health care, research, and medical education: 
a cross-sectional study. Lancet 2012;380(9836):37-43. 
PubMed 
6.  Van Weel C. Chronic diseases in general practice: the 
longitudinal dimension. Eur J Gen Pract. 1996;2(1):17–21. 
PubMed 
7.  Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. 
Association of  comorbidity with disability in older wom-
en: the Women’s Health and Aging Study. J Clin Epidemiol. 
1999;52:27–;37.  PubMed 
8. c2010 [cited 2011 Feb 01].  Available from http://www.
medicalschemes.com/ReadNews.aspx?2
9. Marengoni A, Angleman S, Melis R, Mangialasche 
F, Karp A, Garmen A, et al. Aging with multimorbidi-
ty: a systematic review of  the literature. Ageing Res Rev. 
2011;10(4):430-439.
10.  McLeod H. National Health Insurance Policy brief  
3: The impact of  chronic disease on future NHI [home-
page on the internet].  c2009 [cited 2012 Aug 31]. Avail-
able from http://www.imsa.org.za/national-health-insur-
ance/policy-briefs/
11. Still L. Health care in South Africa. Pietermaritzburg: 
Intrepid printers; 2009.
12. Council for Medical Schemes. Annual report 2010-
2011. [homepage on the internet] c2011 [cited 2014 July 
4]. Available from www.medicalschemes.com
13.  Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Toll-
man SM, Bradshaw D. The burden of  non-communica-
ble diseases in South Africa. Lancet. 2009;374(9693):934 
PubMed -947.
14. Council for Medical Schemes, South Africa. Pre-
scribed minimum benefits (PMB’s) aim to provide you 
with continuous care [homepage on the internet].  c2010 
[cited 2011 Feb 01].  Available from http://www.medi-
calschemes.com/ReadNews.aspx?2
15.  Council for Medical Schemes, South Africa. Medical 
Schemes Act, 131 of  1998. [homepage on the internet] 
c1998 [cited 2014 Feb 01].  Available from https://www.
medicalschemes.com/Content.aspx?130
16.  Schäfer I, von Leitner E-C, Schön G, Koller D, Han-
sen H, Kolonko T, et al. Multimorbidity patterns in the 
elderly: A new approach of  disease clustering identifies 
complex interrelations between chronic conditions. PLoS 
One 2010; 5(12):e15941.  PubMed 
17.  Kirchberger I, Meisinger C, Heier M, Zimmermann 
AK, Thorand B, Autenrieth CS, et al. Patterns of  multi-
morbidity in the aged population. Results from the KO-
RA-Age study. PLoS One 2012; 7(1): e30556.  PubMed 
18.  Grundy SM. Metabolic syndrome: a multiplex car-
diovascular risk factor. J Clin Endocrinol Metab 2007; 
92(2):399-404.
19.  Grundy SM, Cleeman JI, Daniels SR, Donato KA, 
Eckel RH, Franklin BA, et al. Diagnosis and management 
of  the metabolic syndrome: an American Heart Associa-
tion/National Heart, Lung, and Blood Institute Scientific 
statement. Circulation 2005; 112(17):2735-2752.  PubMed 
20.  Cameron AJ, Shaw JE, Zimmet PZ. The metabolic 
syndrome: prevalence in worldwide populations. Endocri-
nol Metab Clin North Am 2004; 33(2):351-375.
21.  Schwellnus, MP, Patel DN, Nossel CJ, Dreyer M, 
Whitesman S, Derman EW. Healthy lifestyle interven-
tions in general practice. Part 6: lifestyle and metabolic 
syndrome. S Afr fam prac. 2009;51(3):177 PubMed -181. 
22.  Motala AA, Mbanya JC, Ramaiya KL. Metabolic syn-
drome in sub-Saharan Africa. Ethn Dis 2009;19(Suppl. 
2):S2.8-S2.10.
23.  Jennings CL, Lambert EV, Collins M, Levitt NS, Goe-
decke JH. The atypical presentation of  the metabolic syn-
drome components in black African women: the relation-
ship with insulin resistance and the influence of  regional 
adipose tissue distribution. Metabolism. 2009;58(2):149 
PubMed -157.
24. Council for Medical Schemes. Annual report 2008-
2009. [homepage on the internet] c2009 [cited 2014 July 
4]. Available from www.medicalschemes.com
25. Snyman J, editor. MIMS Desk Reference annual 
(MDR). Saxonwold: CTP printers; 2008.
26.  Cameron AJ, Shaw JE, Zimmet PZ. The metabolic 
syndrome: prevalence in worldwide populations. Endocri-
nol Metab Clin North Am 2004; 33(2):351-375.
27.  Ervin RB. Prevalence of  metabolic syndrome among 
adults 20 years of  age and over, by sex, age, race and eth-
nicity, and body mass index: United States, 2003-2006. 
Natl Health Stat Report 2009; 13(13):1-7.
28.  Procopiou M, Philippe J. The metabolic syndrome 
and type 2 diabetes: epidemiological figures and country 
specificities. Cerebrovasc Dis 2005; 20(Suppl 1):S2-S8.
29.  Wild SH, Byrne CD. The epidemiology of  the meta-
bolic syndrome and its association with diabetes, cardio-
vascular disease and other conditions. In: Byrne CD, Wild 
African Health Sciences Vol 17 Issue 1, March, 2017       96
SH, editors. The Metabolic syndrome. 2nd ed. Chiches-
ter:  Wiley-Blackwell, 2011; p. 1-18.
30.  Morley JE, Sinclair A. The metabolic syndrome in 
older persons: a loosely defined constellation of  symp-
toms or a distinct entity? Age Ageing 2009; 38(5):494-497. 
PubMed 
31.  Wolff  JL, Starfield B, Anderson G. Prevalence, ex-
penditures, and complications of  multiple chronic con-
ditions in the elderly. Arch Intern Med 2002; 162(20):2269-
2276.  PubMed 
32.  Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. 
Prevalence of  multimorbidity among adults seen in fam-
ily practice. Ann Fam Med 2005; 3(3):223-228.  PubMed 
33. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, 
Spitznagel EL, Steyerberg EW. The changing prevalence 
of  comorbidity across the age spectrum. Crit Rev Oncol 
Hematol 2008; 67(2):124-132.
34.  Steyn HS. Manual for the determination of  effect 
size indices and practical significance [homepage on the 
Internet]. c2009 [updated 2012 Feb; cited 2012 Sept 25]. 
Available from http://www.nwu.ac.za/content/statcs-ef-
fect-size
35.  SAS for Windows [computer program]. Version 9.3. 
Cary (NC): SAS Institute Inc.; 2010. 
36.  American College of  Physicians. Clinical guideline, 
part 1. Screening for thyroid disease. Ann Intern Med 
1998;129(2):141-143.  PubMed 
37.  Vanderpump MPJ. Epidemiology of  thyroid dys-
function – hypothyroidism and hyperthyroidism. Br Med 
Bull 2011; 99(1):39-51.  PubMed 
38. Vanderpump MPJ. The epidemiology ofthyroid dis-
eases. In: Braverman LE, Utiger RD, editors. Werner and 
Ingbar's The Thyroid: A Fundamental and Clinical Text. 
9th ed. Philadelphia: JB Lippincott-Raven, 2005; p. 398-
496.
39.  Díez JJ, Iglesias P. Hypothyroidism in the middle 
aged and elderly: clinical aspects. In: Preedy VR, Burrow 
GN, Watson R, editors. Comprehensive handbook of  
iodine. Nutritional, biochemical, pathological and thera-
peutic aspects. San Diego (CA): Academic press, 2009; p. 
1033-1039.
40.  Park HT, Cho GJ, Ahn KH, Shin JH, Hong SC, Kim 
T, et al. Thyroid stimulation hormone is associated with 
metabolic syndrome in euthyroid postmenopausal wom-
en. Maturitas 2009;301-305.
41.  Lai Y, Wang J, Jiang F, Wang B, Chen Y, Li M, et al. 
The relationship between serum thyrotropin and compo-
nents of  metabolic syndrome. Endocr J 2001;58(1):23-30. 
PubMed 
42.  Iven KA, Schröder E, Brabant G. Thyroid hormones 
and the metabolic syndrome. Eur Thyroid J 2013;2:83-92 
PubMed .
43.  Erdogan M, Canataroglu A, Ganidagli S, Kulaksızoglu 
M. Metabolic syndrome prevalence in subclinic and overt 
hypothyroid patients and the relation among metabolic 
syndrome parameters. J Endocrinol Invest 2011; 34(7):488 
PubMed -492.
44. Waring AC, Rodondi N, Harrison S, Kanaya AM, 
Simonsick EM, Miljkovic I, et al. Thyroid function and 
prevalent and incident metabolic syndrome in older 
adults: the Health, Ageing and Body Composition Study. 
Clin Endocrinol (Oxf) 2012; 76(6):911-918.  PubMed 
45.  Meher LK, Raveendranathan SK, Kota SK, Sarangi 
J, Jali SN. Prevalence of  hypothyroidism in patients with 
metabolic syndrome. Thyroid Res Pract 2013; 10(2):60-64. 
PubMed 
46. Silva JE. Thermogenic mechanism and their hormon-
al regulation. Physiol Rev 2006;86:435-464 PubMed .
47. Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Ef-
fects of  changes in body weight on carbohydrate metab-
olism, catecholamine excretion and thyroid function. Am 
J Clin Nutr 2000;71:1421-1432 PubMed.
48.  De Pergola G, Ciampolillo A, Paolotti S, Trerotoli P, 
Giorgino R. Free triiodothyronine and thyroid stimulating 
hormone are directly associated with waist circumference, 
independently of  insulin resistance, metabolic parameters 
and blood pressure in overweight and obese women. Clin 
Endocrinol (Oxf) 2007; 67(2):265-269.  PubMed 
49. Longi S, Radetti G. Thyroid function and obesity. J 
Clin Res Pediatr Endocrinol 2013;5(Suppl 1):40-44.
50.  Steyn K, Fourie JM, Shepherd J. Detection and mea-
surement of  hypercholesterolaemia in South Africans 
attending general practitioners in private practice - the 
cholesterol monitor. S Afr Med J 1998; 88(12):1569-1574. 
PubMed 
51.  Maritz FJ. Dyslipidaemia in South Africa. In: Steyn 
K, Fourie J, Temple N, editors. Chronic diseases of  life-
style in South Africa: 1995-2005. South Africa: Medical 
Research Council, 2006; p. 97-108.
52. Galassi A, Reynolds K, He J. Metabolic syndrome and 
risk of  cardiovascular disease: a meta-analysis. Am J Med 
2006; 119(10):812-819.  PubMed 
53. Grundy SM. Metabolic syndrome: connecting and 
reconciling cardiovascular and diabetes worlds. J Am Coll 
Cardiol 2006; 47(6):1093-1100.  PubMed 
African Health Sciences Vol 17 Issue 1, March, 201797
54.  Scholze J, Alegria E, Ferri C, Langham S, Stevens W, 
Jeffries D, et al. Epidemiological and economic burden 
of  metabolic syndrome and its consequences in patients 
with hypertension in Germany, Spain and Italy; a preva-
lence-based model. BMC Public Health 2010; 10:529.
55.  Dallongeville J, Cottel D, Arveiler D, Tauber JP, Bing-
ham A, Wagner A, et al. The association of  metabolic dis-
orders with the metabolic syndrome is different in men 
and women. Ann Nutr Metab 2004; 48(1):43-50.  PubMed 
56.  Beigh SH, Jain S. Prevalence of  metabolic syndrome 
and gender differences. Bioinformation 2012; 8(13):613-
616.  PubMed 
57.  Kuk JL, Ardern CI. Age and sex differences the 
clustering of  metabolic syndrome factors: association 
with mortality risk. Diabetes care 2010; 33(11):2457-2461. 
PubMed 
58.  Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gen-
der differences in the metabolic syndrome and their role 
for cardiovascular disease. Clin Res Cardiol 2006; 95(3):136-
147.  PubMed  
59.  Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui 
P, Taylor HS. Gender Differences in Cardiovascular Dis-
ease: Hormonal and Biochemical Influences. Reprod Sci 
2010; 17(6):511-531. PubMed
60.  Rodondi N, den Elzen WP, Bauer DC, Cappola AR, 
Razvi S, Walsh JP, et al. Subclinical hypothyroidism and 
the risk of  coronary heart disease and mortality. JAMA 
2010; 304(12):365-374.  PubMed 
61.  Rodondi N, Newman AB, Vittinghoff   E, de Rekene-
ire N, Satterfield S, Harris TB, et al. Subclinical hypothy-
roidism and the risk of  heart failure, other cardiovascular 
events, and death. Arch Intern Med 2005; 165(21):2460-
2466.  PubMed 
62.  Nanchen D, Gussekloo J, Westendorp RG, Stott 
DJ, Jukema JW, Trompet S, et al. Subclinical thyroid dys-
function and the risk of  heart failure in older persons 
at high cardiovascular risk. J Clin Endocrinol Metab 2012; 
97(3):852-861.
63.  Mayer Jr O, Šimon J, Filipovský J, Plásková M, Pikner 
R. Hypothyroidism in coronary heart disease and its rela-
tion to selected risk factors. Vasc Health Risk Manag 2006; 
2(4):499-506.
64.  Ayankogbe O. Building capacity for African primary 
care research. Afr J Prm Health Care Fam Med 2014;6(1).
65.  National Planning Commission. Promoting health. 
National Development Plan 2030: Our future - make it 
work. [homepage on the Internet] c2012 [cited 2014 Jun 
26]. Available from www.gov.za/documents/download.
php?f=154437.
66.  Garrib A, Stoops N, McKenzie A, Dlamini L, Gov-
ender T, Rohde J, et al. An evaluation of  the district 
health information system in rural South Africa. Afr Med 
J 2008;98:549-552 PubMed.
67.  Cline GB, Luiz JM. Information technology systems 
in public sector health facilities in developing countries: 
the case of  South Africa. BMC Med Inform Decis Mak 
2013;13:13.
African Health Sciences Vol 17 Issue 1, March, 2017       98
